EGFR基因突變與非小細(xì)胞肺癌相關(guān)研究進(jìn)展

任會(huì)強(qiáng) 董麗儒 宋旭東

華北理工大學(xué)附屬醫(yī)院病理科 河北唐山 063000

?

EGFR基因突變與非小細(xì)胞肺癌相關(guān)研究進(jìn)展

任會(huì)強(qiáng) 董麗儒 宋旭東

華北理工大學(xué)附屬醫(yī)院病理科 河北唐山 063000

非小細(xì)胞肺癌 EGFR EGFR基因突變 EGFR-TKIs

目前，肺癌依然是導(dǎo)致人類腫瘤性致死的首位疾病，全球每年因肺癌死亡的人數(shù)超過(guò)100萬(wàn)，其中80%～90%的患者為非小細(xì)胞肺癌(non-small-cell lung cancer,NSCLC)[1]。NSCLC占原發(fā)性肺癌的80%～85%[2]。雖然對(duì)肺癌的檢測(cè)和治療手段在不斷的進(jìn)步，但大多數(shù)肺癌患者預(yù)后仍然很差，5年生存率僅為10%～15%[3]。近年來(lái)，隨著精準(zhǔn)醫(yī)學(xué)的提倡、發(fā)展，個(gè)體化治療成為NSCLC治療的新方向。這種治療基于腫瘤的分子特征，針對(duì)表皮生長(zhǎng)因子相關(guān)受體(epidermal growth factor receptor，EGFR)基因突變位點(diǎn)選擇最佳的治療方案，EGFR酪氨酸激酶抑制劑(EGFR tyrosine kinase inhibitors ,EGFR-TKIs)治療對(duì)有EGFR基因突變的患者較沒(méi)有EGFR基因突變的患者效果更好[4～7],使患者獲得最好的療效，延長(zhǎng)其生存時(shí)間、提高生活質(zhì)量。所以檢測(cè)EGFR基因是否突變成為預(yù)測(cè)EGFR-TKIs療效的指標(biāo)?，F(xiàn)對(duì)EGFR基因突變與NSCLC相關(guān)研究的進(jìn)展綜述如下。

1 EGFR的分子生物學(xué)結(jié)構(gòu)及功能

EGFR屬于酪氨酸激酶I型受體家族，其家族成員主要包括EGFR HER1、HER2、HER3、HER4四種同源受體。研究發(fā)現(xiàn)，EGFR廣泛分布于各種上皮細(xì)胞的細(xì)胞膜上，分為胞外區(qū)、跨膜區(qū)、胞內(nèi)區(qū)三個(gè)部分。目前報(bào)道EGFR配體有表皮生長(zhǎng)因子EGF、轉(zhuǎn)化生長(zhǎng)因子TGF、結(jié)合肝素的EGF、雙調(diào)蛋白、B-cellulin等[8]。EGFR主要信號(hào)轉(zhuǎn)導(dǎo)途有RAS-RAF-MEK-ERK-MAPK通路、PLC-γ通路、PI3K-PDK通路和JAK-STAT通路[9]。

EGFR的基因位于7號(hào)染色體短臂7p12-14區(qū)，共118kb，由28個(gè)外顯子組成。其酪氨酸激酶功能區(qū)由外顯子18-24編碼，其中外顯子18-20編碼N端半段結(jié)構(gòu)(N terminal half,N-Lobe),外顯子21-24編碼C端半段結(jié)構(gòu)(C terminal half,C-Lobe)。EGFR是癌癥生長(zhǎng)的刺激因素。EGFR基因突變可使EGFR在沒(méi)有配體與其結(jié)合的情況下激活下游分子，從而引起腫瘤等疾病的發(fā)生[10]。有研究顯示[11]EGFR基因突變和蛋白的過(guò)表達(dá)都可以激化下游信號(hào)通路，這與癌癥的的發(fā)生有密切的關(guān)系，特別是肺癌。

2 EGFR基因突變的特點(diǎn)

研究表明[12]EGFR基因突變主要包括18外顯子突變和19外顯子的缺失突變(主要是19外顯子的多個(gè)核苷酸框架缺失突變引起4個(gè)氨基酸的缺失) 、20外顯子的插入或T790M和21外顯子上的點(diǎn)突變引起858位點(diǎn)氨基酸替代突變。另一項(xiàng)研究顯示[13]EGFR基因的28個(gè)外顯子中，第18-21外顯子編碼酪氨酸激酶區(qū)；EGFR基因突變部位分散在整個(gè)酪氨酸激酶區(qū)，19外顯子的缺失突變和21外顯子的L858R突變是最常見的突變類型。相似的研究表明[16]EGFR基因的經(jīng)典突變是19外顯子的缺失突變和21外顯子的L858R突變，兩者分別占EGFR基因突變的45%和40%。另一項(xiàng)試驗(yàn)[17]表明19外顯子的突變率最高，占全部突變的60%以上。Fukui等[18]研究發(fā)現(xiàn)EGFR基因突變有以下類型:19外顯子的缺失突變、密碼子719處的點(diǎn)突變(G719X)、20外顯子的插入突變、21外顯子的點(diǎn)突變。19外顯子的缺失突變包括從亮氨酸-747到谷氨酸-749，定位于酪氨酸激酶C螺旋區(qū)N端，此處缺失發(fā)生率為44%。20外顯子出現(xiàn)的突變發(fā)生率為5%，G719X發(fā)生率為4%。在外顯子21處的點(diǎn)突變是最常見的EGFR酪氨酸激酶區(qū)點(diǎn)突變，發(fā)生率為41%。Lynch等[14,19]均報(bào)道發(fā)現(xiàn)在EGFR基因TK區(qū)域外顯子18-23存在基因突變。該突變導(dǎo)致EGFR基因上ATP結(jié)合位點(diǎn)的缺口，該位點(diǎn)正是酪氨酸激酶抑制劑(TKIs)的結(jié)合位點(diǎn)。據(jù)研究表明[20]20%的NSCLC患者有EGFR基因突變，主要位于酪氨酸激酶區(qū)域的19外顯子堿基對(duì)缺失(delE746_A750，占54%)或21外顯子的點(diǎn)突變(L858R，占43%)。鄭軍等[21]研究214例NSCLC EGFR基因總突變率為45.8%(97/214)。其中18外顯子突變發(fā)生率為0.93%(2/214)、19外顯子突變發(fā)生率為22.0%(47/214)，均為缺失突變；20外顯子突變發(fā)生率為2.3%(5/214)，其中有4例缺失突變，1例T790M突變；21外顯子突變率為20.6%(44/214)，均為L(zhǎng)858R突變。研究中出現(xiàn)2例19外顯子的缺失突變和21外顯子的L858R突變的雙重突變，此現(xiàn)象提示肺癌患者中可存在EGFR基因聯(lián)合突變。

EGFR基因突變并非都有良好的分子靶向治療效果，T790M突變則提示NSCLC對(duì)TKI耐藥。T790M位于20外顯子ATP結(jié)合口袋，被命名為“看門人殘留”，其突變是在激酶域的790位點(diǎn)蛋氨酸替代蘇氨酸，導(dǎo)致位阻效應(yīng)，減弱EGFR與ATP的結(jié)合力；ATP結(jié)合口袋對(duì)ATP的結(jié)合能力因T790M基因突變而增強(qiáng)，從而與TKIs競(jìng)爭(zhēng)性的結(jié)合ATP；T790M突變也可使L858R突變的EGFR基因與ATP親和力增強(qiáng)，這三個(gè)原因就是耐藥發(fā)生的機(jī)制[11,22]。沒(méi)有使用TKIs治療的患者，也會(huì)出現(xiàn)T790M突變，突變率為2.7%～40%[23]。所有NSCLC(有19外顯子缺失突變和21外顯子點(diǎn)突變)患者在接受EGFR-TKIs治療后，都會(huì)發(fā)生獲得性耐受，其中50%患者20外顯子(T790M)會(huì)有T790M基因二次突變，這種突變?cè)谥委熢缙诤苌侔l(fā)生[24,25]。T790M基因突變還可與其他突變同時(shí)存在，如L858R 和 D761Y。與L858R突變同時(shí)存在時(shí)，T790M基因可增強(qiáng)磷酸化活性。突變共存可導(dǎo)致肺癌細(xì)胞存活，這表明T790M基因是一個(gè)致癌基因[26,27]。此外還存在非T790M的二次突變，主要有D761Y、L747S和T854A[28～30]。這些突變導(dǎo)致EGFR基因突變對(duì)EGFR-TKIs的敏感性下降，其耐藥的機(jī)制還不清楚[11]。另外，最近的研究[30,31]顯示，在EGFR基因20外顯子上發(fā)現(xiàn)了一種新插入突變(Pro772-His773insGlnCysPro)，這種突變發(fā)生于不吸煙的患者[32,33]。但這些非T790M的突變發(fā)生率很低。

3 EGFR基因突變與NSCLC臨床病理學(xué)特征

有研究[34,35]顯示，大約有10%～30%的NSCLC患者發(fā)生EGFR基因突變。張靜等[36]在檢測(cè)170例NSCLC研究中發(fā)現(xiàn)腺癌、鱗癌和大細(xì)胞癌EGFR基因突變的檢出率分別為:60.3%(82/136)、0%(0/24)和20%(2/10)。此研究顯示肺腺癌患者中EGFR基因突變率明顯高于鱗癌及大細(xì)胞癌患者，肺腺癌與非腺癌EGFR基因突變比較差異有統(tǒng)計(jì)學(xué)意義，136例腺癌中細(xì)支氣管肺泡癌(15/22)和其他類型腺癌(67/114)的EGFR基因突變率差異無(wú)統(tǒng)計(jì)學(xué)意義。鄭軍等[21]的研究顯示，在肺腺癌組織中的EGFR基因突變率為50.3%(93/185)，明顯高于肺鱗狀細(xì)胞癌17.2%(5/29)。Hisayuki等[20]研究顯示，肺腺癌EGFR基因突變率為40%。另一項(xiàng)研究發(fā)現(xiàn)[38]肺腺癌和肺腺鱗癌的突變發(fā)生率高于其他病理類型。

韓寶惠等[37]發(fā)現(xiàn)EGFR基因突變主要見于女性、腺癌及腺鱗癌等患者。Paez等研究發(fā)現(xiàn)[19]EGFR基因突變與性別、種族、吸煙、病理類型有關(guān)，亞洲人群、女性、非吸煙、肺腺癌的NSCLC患者突變率較高,女性和非吸煙的NSCLC患者EGFR基因突變率高于男性和吸煙患者。后續(xù)的多項(xiàng)臨床研究[38,39]再次證實(shí)女性、不吸煙的NSCLC患者EGFR突變率明顯高于男性和吸煙的NSCLC患者。另一項(xiàng)研究發(fā)現(xiàn)[40]女性NSCLC患者的EGFR突變率高于男性，并且非吸煙NSCLC患者EGFR突變率高于吸煙者。國(guó)外一項(xiàng)研究[20]顯示，女性NSCLC患者EGFR基因突變率為42%，亞洲種族NSCLC患者EGFR基因突變率為30%,非吸煙NSCLC患者EGFR基因突變率為51%。國(guó)內(nèi)一項(xiàng)研究[21]顯示，女性患者EGFR突變率為57.0%(57/100),高于男性[36.0%(41/114)]。張靜等[36]對(duì)170例NSCLC患者的EGFR基因突變情況的研究表明，EGFR基因突變常見于女性、不吸煙、腫瘤大小≤3cm且分化程度較好的NSCLC患者。Dearden等[41]研究顯示，亞洲地區(qū)NSCLC患者EGFR基因突變率為47.9%。該數(shù)據(jù)與Midha等[42]對(duì)亞洲地區(qū)NSCLC患者EGFR基因突變情況研究所得的數(shù)據(jù)(47%)相近。并且，亞洲地區(qū)的NSCLC女性患者的EGFR基因突變率高于男性患者(60%:37%)，該地區(qū)非吸煙NSCLC患者EGFR基因突變率高于吸煙患者(64%:33%)。因此，EGFR基因突變通常發(fā)生在NSCLC患者的以下亞群：非吸煙、女性、東亞人群、支氣管肺泡腺癌和中分化的腫瘤患者[33,43,44]。研究顯示[41]盡管EGFR基因突變高發(fā)于女性、非吸煙和亞洲人群等NSCLC患者，但是也可以發(fā)生在這三類人群之外的患者中。Yuankai等[45]的研究發(fā)現(xiàn)超過(guò)50%的NSCLC患者的EGFR基因突變不是女性非吸煙患者。

劉紅雨等[40]研究發(fā)現(xiàn), EGFR基因19外顯子和21外顯子的突變與肺癌患者的年齡、臨床分期、腫瘤大小、轉(zhuǎn)移情況等沒(méi)有明顯的關(guān)系。有研究[37]顯示EGFR基因突變與患者的年齡、淋巴結(jié)是否轉(zhuǎn)移及疾病pTNM分期等無(wú)相關(guān)性。相似的研究[21]顯示EGFR基因突變率在患者年齡分組中無(wú)顯著性差異。但多數(shù)研究報(bào)道[46～48]顯示EGFR基因突變?cè)谟辛馨徒Y(jié)轉(zhuǎn)移的NSCLC患者中的發(fā)生率高于無(wú)淋巴結(jié)轉(zhuǎn)移的患者，而與腫瘤臨床分期及病理分級(jí)無(wú)顯著性相關(guān)。

4 EGFR基因突變與NSCLC臨床治療

有一些EGFR基因突變會(huì)增強(qiáng)EGFR-TKIs的敏感性，比如L858R和19外顯子的缺失。21外顯子L858R位點(diǎn)突變可減低ATP結(jié)合的親和力，這種ATP親和力的降低實(shí)質(zhì)上建立了一個(gè)“治療窗口”，這種致癌性的EGFR基因突變可更容易的被TKIs抑制，從而替代親和力低的ATP[22]。這就為EGFR-TKIs治療有19和21位點(diǎn)突變的NSCLC的患者提供了方案。第一代EGFR-TKIs(吉非替尼和埃羅替尼)可逆的競(jìng)爭(zhēng)ATP結(jié)合位點(diǎn)，從而阻止EGFR導(dǎo)致的下游信號(hào)激活[49]。TKIs也可導(dǎo)致腫瘤細(xì)胞的死亡[11]。有研究[50,51]顯示，與應(yīng)用卡鉑/紫杉醇治療的患者的中位無(wú)進(jìn)展生存期(progression free survival，PFS)相比，吉非替尼可顯著延長(zhǎng)有EGFR基因突變NSCLC患者的中位PFS(平均為9.5:6.3個(gè)月)。據(jù)一些研究顯示[52,53]，吉非替尼與卡鉑/紫杉醇作為一線藥物治療有EGFR基因突變的亞洲患者，中位PFS 9.2:6.3個(gè)月(P<0.0001)；埃羅替尼與卡鉑/紫杉醇化療作為一線藥物治療EGFR基因突變的亞洲患者進(jìn)行療效比較，中位PFS 13.1:4.6個(gè)月?？ㄣK/紫杉醇較EGFR-TKIs對(duì)有EGFR基因擴(kuò)增的NSCLC患者的療效好，并且對(duì)于沒(méi)有EGFR基因突變的患者，卡鉑/紫杉醇較EGFR-TKIs療效顯著(中位 PFS 5.5:1.5個(gè)月，P<0.001)[19]。在有EGFR基因突變的NSCLC患者(n=261)，吉非替尼比化療的PFS長(zhǎng)，相對(duì)危險(xiǎn)比更高(71.2%：47.3%)；相反，在無(wú)EGFR基因突變的群組患者，PFS顯著縮短，相對(duì)危險(xiǎn)比更低(1.1%:23.5%)[23]。因此再次證實(shí)，EGFR基因突變位點(diǎn)決定EGFR-TKIs的臨床應(yīng)用療效。然而，所有的患者初次應(yīng)用吉非替尼和埃羅替尼效果非常顯著，6到12個(gè)月之后會(huì)產(chǎn)生獲得性耐藥[24,25]。一些耐藥機(jī)制研究已經(jīng)發(fā)現(xiàn)[54]大約50%的獲得性耐藥是由于EGFR基因20外顯子T790M的二次突變導(dǎo)致的，T790M突變會(huì)減低EGFR-TKIs與ATP結(jié)合的敏感度，但是還有30%的獲得性耐受病例仍然無(wú)法解釋[29]，這需要進(jìn)一步的研究。

Oxnard等[55]發(fā)現(xiàn)TKIs治療后活檢有T790M突變的患者比沒(méi)有突變的患者的預(yù)后生存時(shí)間更長(zhǎng)(19:12個(gè)月)。Kuiper等[56]對(duì)66例有EGFR基因突變的NSCLC患者研究顯示，用EGFR-TKIs治療post-TKIs活檢有T790M突變的患者比沒(méi)有突變患者有更長(zhǎng)的PFS(14.2:11.1)個(gè)月，并且有更長(zhǎng)的總生存期(45.9:29.8)個(gè)月。腫瘤有高的EGFR基因拷貝數(shù)，并有EGFR基因突變的患者，吉非替尼能顯著延長(zhǎng)其PFS；腫瘤有高的EGFR基因拷貝數(shù)，沒(méi)有EGFR基因突變的患者，應(yīng)用吉非替尼比應(yīng)用卡鉑/紫杉醇的PFS還要短[23]，這再一次表明EGFR基因突變是應(yīng)用EGFR-TKIs治療的指針。另有研究[57]顯示，應(yīng)用EGFR-TKIs治療出現(xiàn)T790M突變的患者較沒(méi)有出現(xiàn)此突變的患者有更長(zhǎng)的PFS。

西妥昔單抗是一單克隆抗體，通過(guò)結(jié)合胞外區(qū)域來(lái)抑制EGFR基因，從而封鎖配體依賴性受體的激活[58];也可通過(guò)調(diào)節(jié)受體的內(nèi)吞和退化來(lái)抑制EGFR信號(hào)，因此也可減弱配體依賴的EGFR信號(hào)[32]。研究顯示[59]西妥昔單抗與雙鉑化療聯(lián)用治療NSCLC相比,患者的總生存時(shí)間為(11.3:10.1)個(gè)月，用西妥昔單抗治療的患者有更長(zhǎng)的總生存時(shí)間。

Federico等[60]研究15例19外顯子缺失突變和7例21外顯子點(diǎn)突變的患者在接受化療時(shí)發(fā)現(xiàn)，19外顯子缺失突變的預(yù)后更好。Jackman等[61]研究36例接受EGFR-TKIs治療的19和21外顯子突變的NSCLC患者預(yù)后顯示，19(delp.729-761)比L858R突變的患者的時(shí)間進(jìn)程有顯著提高(24:10個(gè)月)，有19外顯子突變的患者比21外顯子突變的患者有更高的危險(xiǎn)比(73%:50%)。這種現(xiàn)象還沒(méi)有一個(gè)科學(xué)的解釋，可能與19外顯子對(duì)EGFR-TKI的敏感性更高有關(guān)[62]。這些研究表明，不同的EGFR基因突變的患者腫瘤有著不同的生物學(xué)特性。

[1] Jemal A,Siegel R,Ward E，et al.CA:a cancer journal of clinicians[J].Cancer Stat,2007,57(1): 43-66

[2] Crinò L,Weder W,Meerbeeck J,et al.Early stage and locally advanced(non-metastatic)non-small-cell lung cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(5):103-115

[3] Jemal A,Siegel R,Ward. E,et al.Cancer statistics[J].CA Cancer J Clin,2006,56(2):106-130

[4] Rafael R,Enric C,Radj G,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncology,2012,13(3):239-246

[5] James CY,Yi-Long W,Valorie C,et al.Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)[J].Lung Cancer,2013,83(2):174-181

[6] Jean YD,Gyula O,Manuel C,et al.Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status[J].Journal of Thoracic Oncology,2014, 9(9):1345-1353

[7] Caicun Z,Yi-Long W,Gongyan C,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,12(8): 735-742

[8] Han X.Research on EGFR in gastric cancer and its significance[J].Chinese Clinical Oncology,2010,15(2):173-176

[9] Cao C,Lu S,Sowa A,et al.Priming with EGFR tyrosine kinase inhibitor and EGFsensitizes ovarian cancer cells to respond to chemotherapeutical drugs[J].Cancer Lett,2008,266(2):249-262

[10] Roseann M,Audrey F,Youngjoo K,et al.Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib[J].Cancer Research,2007,67(5):2325-2330

[11] Huang L,Fu L.Mechanisms of resistance to EGFR tyrosine kinase inhibitors[J].Acta Pharmaceutica Sinica B, 2015, 358(5):390-401

[12] Base lga J.Why the epidermal growth factor receptor[J].Oncologist, 2002,7(4):2-8

[13] Yoshida T,Ishii G,Goto K,et al.Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma[J].Journal of Cancer Research & Clinical Oncology,2013,139(10):1691-1700

[14] Lynch TJ,Bell DW,Raffaella S,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].New England Journal of Medicine,2004,350(21):2129-2139

[15] Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma[J].Lab Invest,2013,94(2):129-137

[16] William P, Juliann C. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer[J].Nature Reviews Cancer,2010,10(11):760-774

[17] Yu HA,Arcila ME,Natasha R,et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J].Clinical Cancer Research,2013, 19(8):2240-2247

[18] Fukui T,Mitsudomi T.Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers[J].Cancer Science,2008,98(12):1817-1824

[19] Paez JG,Janne PA,Lee JC,et al.EGFR mutation in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-1500

[20] Hisayuki S,Li L,Takao T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J].Journal of the National Cancer Institute, 2005,97(5):339-346

[21] 鄭 軍,謝貴元,李 姣,等.非小細(xì)胞肺癌EGFR基因突變的臨床意義研究[J].中國(guó)腫瘤臨床,2014,41(14):904-907

[22] Yun CH,Mengwasser KE,Toms AV,et al.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J].Proc Natl Acad Sci U S A,2008,105(6):2070-2075

[23] Tony S.Mok,MD,Yi LW,et al.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957

[24] Masahiro F, Yi-Long W, Sumitra T, et al.Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. Journal of Clinical Oncology,2011, 29(21):2866-2874

[25] David J,William P,Riely G J,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].Journal of Clinical Oncology,2010, 28(2):357-360

[26] Smith DL,Acquaviva J,Sequeira M,et al.The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer[J].Targeted Oncology,2015,10(2):235-245

[27] Costa DB,Balázs H,Amit K,et al.BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J].Plos Medicine,2007, 4(10):1669-1679

[28] Shinichi T,Hiroshi D,Akiko U,et al.The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor[J].Clinical Cancer Research An,2007,13(11):3431-3431

[29] Bean J,Riely G J,Balak M,et al.Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma[J].Clinical Cancer Research,2008,14(22):7519-7525

[30] Woo HS,Ahn HK,Lee HY,et al.Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors[J].Investigational New Drugs,2014,32(6):1311-1315

[31] Khan NA,Saied M,Mirshahidi HR.A novel insertion mutation on exon 20 of epidermal growth factor receptor,conferring resistance to erlotinib[J].Case Reports in Oncology,2014,7(2):491-496

[32] Christian B,Inger Helene M,Espen S.Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis[J].Experimental Cell Research,2012,318(20):2578-2591

[33] Hiroshi H,Hidefumi S,Neal L,et al.A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma[J].Japanese Journal of Clinical Oncology,2006,36(2):69-75

[34] Chen YM.Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer[J].Journal of the Chinese Medical Association,2013, 76(5):249-257

[35] Shiau C J,Babwah J P,Gilda DC,et al.Sample features associated with success rates in population-based EGFR mutation testing[J].Journal of Thoracic Oncology,2014,9(7):947-956

[36] Zhang J,Liang ZY,Gao J,et al.Relationship between the mutations of epidermal growth factor receptor gene and k-ras Gene andthe clinicopathological features of non-small cell lung cancers[J].Med J Peking Union Med Coll Hosp,2010,1(1):53-93

[37] 韓寶惠,黃進(jìn)肅,董強(qiáng)剛,等.176例非小細(xì)胞肺癌的EGFR基因突變分析[J].中華腫瘤雜志,2006,28(9):686-690

[38] Ren RX,Li JY,Li XF,et al.Detection of epidermal growth factor receptor mutations in small specimens of non-small cell lung cancer by amplification refractory mutation system[J].Zhong Liu, 2012,32(11):929-935

[39] Wang F,Fu S,Tang T,et al.Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers[J].Zhonghua Bing Li Xue Za Zhi,2011,40(10):664-666

[40] 劉紅雨,李 穎,陳 鋼,等.187例非小細(xì)胞肺癌中EGFR基因突變和擴(kuò)增的檢測(cè)及其臨床意義[J].中國(guó)肺癌雜志,2009,12(12):1219-1228

[41] Dearden S,Stevens J,Y-L W,et al.Mutation incidence and coincidence in non small-cell lung cancer:meta-analyses by ethnicity and histology(mutMap)[J].Annals of Oncology,2013,24(9):2371-2376

[42] Midha A,Dearden S,Mccormack R.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)[J]. American Journal of Cancer Research, 2015, 5(9):2892-2911

[43] Choi YH,Lee JK, Kang HJ,et al.Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer[J].Journal of Thoracic Oncology,2010,5(12):1949-1952

[44] Eckart L,Ronald S,Marc R,et al.Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion[J].Journal of Thoracic Oncology,2011, 6(1):199-202

[45] Yuankai S,Joseph Siu-Kie A,Sumitra T,et al.A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)[J].Journal of Thoracic Oncology,2014,9(2):154-162

[46] Shiozawa T,Ishii G,Goto K,et al.Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung[J].Pathology International,2013,63(2):77-84

[47] Song J,Zhong R,Huang H,et al.Combined Treatment with Epimedium koreanum Nakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells[J].Nutr Cancer,2014,66(4):682-689

[48] Dario de Biase,Michela Visani,Umberto Malapelle,et al.Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)[J].Plos One,2013,8(12):83607-83607

[49] Yuxin L,Xian W,Hongchuan J.EGFR-TKI resistance in NSCLC patients:mechanisms and strategies[J].American Journal of Cancer Research,2014,4(5):411-435

[50] Masahiro F,Yi-Long W,Sumitra T,et al.Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. Journal of Clinical Oncology,2011, 29(21):2866-2874

[51] Wu YL,Fukuoka M,Mok TS,et al.Tumor response and health-related quality of life in clinically selected patientsfrom Asia with advanced non-small-cell lung cancer treated with first-line gefitinib:post hocanalyses from the IPASS study[J].Lung Cancer ,2013,81(2):280-287

[52] Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J].Lancet Oncology,2010,11(2):1697-1700

[53] Caicun Z,Yi Long W,Gongyan C,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,12 (8):735-742

[54] Stewart EL,Tan SZ,Liu G,et al.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review[J].Translational Lung Cancer Research,2015,4(1):67-81

[55] Oxnard GR,Arcila ME,Sima CS,et al.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation[J].Clinical Cancer Research,2010,17(6):1616-1622

[56] Kuiper JL,Heideman DA,Thunnissen E,et al.Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients1[J].Lung Cancer,2014,85(1):19-24

[57] Hata A,Katakami N,Yoshioka H,et al.Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations[J].Cancer.2013,119(24): 4325-4332

[58] Antonio R.Cetuximab and non-small-cell lung cancer:end of the story?[J].Lancet Oncology, 2013,14(13):1251-1253

[59] Pirker R,Pereira JR,Szczesna A,et al.Cetuximab pluschemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase IIItrial[J].Lancet,2009, 373(9674):1525-1531

[60] Federico C,Claudia L,Claudio L,et al.EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)[J].Journal of Thoracic Oncology,2007,2(5):423-429

[61] Jackman DM,Yeap BY,Sequist LV,et al.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J].Clinical Cancer Research,2006,12(13):3908-3914

[62] Fang ZW.EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer[J].Drug Design Development & Therapy,2014,8(14):1595-1611

(2016-05-05 收稿)(張愛國(guó) 編輯)

2016年河北省政府資助臨床醫(yī)學(xué)優(yōu)秀人才培養(yǎng)和基礎(chǔ)課題研究項(xiàng)目(編號(hào)：361036)。

任會(huì)強(qiáng)(1988-)，男，碩士研究生。研究方向：肺腫瘤。

宋旭東。

R 73

A

2095-2694(2016)05-413-08